Finally, more than 40% of patients initially at very high CKD risk were at high, moderate, or low/no CKD risk at 12 months ( Figure 4D )
Some patients experience some form of gastrointestinal discomfort while taking semaglutide
When thyroid function is disruptedwhether through hypothyroidism, hyperthyroidism, or autoimmune thyroid diseasemetabolism becomes either sluggish or overactive, making weight management significantly more difficult
Those absences matter more here because GLP-1 medications already slow transit and shift fluid balance, so constipation and electrolyte swings end up with two causes stacked on each other instead of one
While some supplement ingredients have shown promise in limited studies related to metabolic health and weight management, they do not have the same effects as GLP-1 drugs, Ventura said